176 related articles for article (PubMed ID: 21113977)
1. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Advani AS; Gundacker HM; Sala-Torra O; Radich JP; Lai R; Slovak ML; Lancet JE; Coutre SE; Stuart RK; Mims MP; Stiff PJ; Appelbaum FR
Br J Haematol; 2010 Dec; 151(5):430-4. PubMed ID: 21113977
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
3. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Advani AS; McDonough S; Coutre S; Wood B; Radich J; Mims M; O'Donnell M; Elkins S; Becker M; Othus M; Appelbaum FR
Br J Haematol; 2014 May; 165(4):504-9. PubMed ID: 24579885
[TBL] [Abstract][Full Text] [Related]
4. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
O'Connor D; Sibson K; Caswell M; Connor P; Cummins M; Mitchell C; Motwani J; Taj M; Vora A; Wynn R; Kearns PR
Br J Haematol; 2011 Aug; 154(4):482-5. PubMed ID: 21689087
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
[TBL] [Abstract][Full Text] [Related]
7. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Cooper TM; Alonzo TA; Gerbing RB; Perentesis JP; Whitlock JA; Taub JW; Horton TM; Gamis AS; Meshinchi S; Loken MR; Razzouk BI
Cancer; 2014 Aug; 120(16):2482-9. PubMed ID: 24771494
[TBL] [Abstract][Full Text] [Related]
8. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.
Barba P; Sampol A; Calbacho M; Gonzalez J; Serrano J; Martínez-Sánchez P; Fernández P; García-Boyero R; Bueno J; Ribera JM
Am J Hematol; 2012 Jun; 87(6):631-4. PubMed ID: 22431002
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
10. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Zeidan AM; Ricklis RM; Carraway HE; Yun HD; Greer JM; Smith BD; Levis MJ; McDevitt MA; Pratz KW; Showel MM; Gladstone DE; Gore SD; Karp JE
Br J Haematol; 2012 Jul; 158(2):198-207. PubMed ID: 22594769
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
15. Clofarabine combinations as acute myeloid leukemia salvage therapy.
Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Faderl S; Verstovsek S; Cortes J; Ravandi F; Beran M; Garcia-Manero G; Ferrajoli A; Estrov Z; O'Brien S; Koller C; Giles FJ; Wierda W; Kwari M; Kantarjian HM
Blood; 2006 Jul; 108(1):45-51. PubMed ID: 16403905
[TBL] [Abstract][Full Text] [Related]
17. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
[TBL] [Abstract][Full Text] [Related]
19. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
[TBL] [Abstract][Full Text] [Related]
20. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]